747 related articles for article (PubMed ID: 11529247)
1. A phase I/II dose escalation and activity study of intravenous injections of OCaP1 for subjects with refractory osteosarcoma metastatic to lung.
Benjamin R; Helman L; Meyers P; Reaman G
Hum Gene Ther; 2001 Aug; 12(12):1591-3. PubMed ID: 11529247
[TBL] [Abstract][Full Text] [Related]
2. Anti-tumor efficacy of a transcriptional replication-competent adenovirus, Ad-OC-E1a, for osteosarcoma pulmonary metastasis.
Li X; Jung C; Liu YH; Bae KH; Zhang YP; Zhang HJ; Vanderputten D; Jeng MH; Gardner TA; Kao C
J Gene Med; 2006 Jun; 8(6):679-89. PubMed ID: 16570242
[TBL] [Abstract][Full Text] [Related]
3. In vivo suppression of osteosarcoma pulmonary metastasis with intravenous osteocalcin promoter-based toxic gene therapy.
Shirakawa T; Ko SC; Gardner TA; Cheon J; Miyamoto T; Gotoh A; Chung LW; Kao C
Cancer Gene Ther; 1998; 5(5):274-80. PubMed ID: 9824046
[TBL] [Abstract][Full Text] [Related]
4. A phase I trial of genetically modified Salmonella typhimurium expressing cytosine deaminase (TAPET-CD, VNP20029) administered by intratumoral injection in combination with 5-fluorocytosine for patients with advanced or metastatic cancer. Protocol no: CL-017. Version: April 9, 2001.
Cunningham C; Nemunaitis J
Hum Gene Ther; 2001 Aug; 12(12):1594-6. PubMed ID: 11529249
[TBL] [Abstract][Full Text] [Related]
5. Osteogenic sarcoma of the extremity with detectable lung metastases at presentation. Results of treatment of 23 patients with chemotherapy followed by simultaneous resection of primary and metastatic lesions.
Bacci G; Mercuri M; Briccoli A; Ferrari S; Bertoni F; Donati D; Monti C; Zanoni A; Forni C; Manfrini M
Cancer; 1997 Jan; 79(2):245-54. PubMed ID: 9010097
[TBL] [Abstract][Full Text] [Related]
6. Can cure in patients with osteosarcoma be achieved exclusively with chemotherapy and abrogation of surgery?
Jaffe N; Carrasco H; Raymond K; Ayala A; Eftekhari F
Cancer; 2002 Nov; 95(10):2202-10. PubMed ID: 12412175
[TBL] [Abstract][Full Text] [Related]
7. Chemogene therapy: osteocalcin promoter-based suicide gene therapy in combination with methotrexate in a murine osteosarcoma model.
Cheon J; Ko SC; Gardner TA; Shirakawa T; Gotoh A; Kao C; Chung LW
Cancer Gene Ther; 1997; 4(6):359-65. PubMed ID: 9408606
[TBL] [Abstract][Full Text] [Related]
8. The Challenge of Developing New Therapies for Childhood Cancers.
Balis FM
Oncologist; 1997; 2(1):I-II. PubMed ID: 10388032
[TBL] [Abstract][Full Text] [Related]
9. A conditional replication-competent adenoviral vector, Ad-OC-E1a, to cotarget prostate cancer and bone stroma in an experimental model of androgen-independent prostate cancer bone metastasis.
Matsubara S; Wada Y; Gardner TA; Egawa M; Park MS; Hsieh CL; Zhau HE; Kao C; Kamidono S; Gillenwater JY; Chung LW
Cancer Res; 2001 Aug; 61(16):6012-9. PubMed ID: 11507044
[TBL] [Abstract][Full Text] [Related]
10. Primary osteogenic sarcoma with pulmonary metastasis: clinical results and prognostic factors in 91 patients.
Wu PK; Chen WM; Chen CF; Lee OK; Haung CK; Chen TH
Jpn J Clin Oncol; 2009 Aug; 39(8):514-22. PubMed ID: 19525290
[TBL] [Abstract][Full Text] [Related]
11. Technology evaluation: tgDCC-E1A, targeted genetics/MD Anderson.
Wagner JA
Curr Opin Mol Ther; 1999 Apr; 1(2):266-70. PubMed ID: 11715950
[TBL] [Abstract][Full Text] [Related]
12. Growth suppression of established human osteosarcoma lung metastases in mice by aerosol gene therapy with PEI-p53 complexes.
Densmore CL; Kleinerman ES; Gautam A; Jia SF; Xu B; Worth LL; Waldrep JC; Fung YK; T'Ang A; Knight V
Cancer Gene Ther; 2001 Sep; 8(9):619-27. PubMed ID: 11593330
[TBL] [Abstract][Full Text] [Related]
13. Treatment of osteogenic sarcoma. II. Aggressive resection of pulmonary metastases.
Rosenburg SA; Flye MW; Conkle D; Seipp CA; Levine AS; Simon RM
Cancer Treat Rep; 1979 May; 63(5):753-6. PubMed ID: 287554
[TBL] [Abstract][Full Text] [Related]
14. [Tuberculosis in compromised hosts].
Kekkaku; 2003 Nov; 78(11):717-22. PubMed ID: 14672050
[TBL] [Abstract][Full Text] [Related]
15. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
16. Clinical protocol. An open-label, phase I, single administration, dose-escalation study of ADGVPEDF.11D (ADPEDF) in neovascular age-related macular degeneration (AMD).
Rasmussen H; Chu KW; Campochiaro P; Gehlbach PL; Haller JA; Handa JT; Nguyen QD; Sung JU
Hum Gene Ther; 2001 Nov; 12(16):2029-32. PubMed ID: 11727737
[TBL] [Abstract][Full Text] [Related]
17. Bisphosphonates for cancer patients: why, how, and when?
Body JJ; Mancini I
Support Care Cancer; 2002 Jul; 10(5):399-407. PubMed ID: 12136223
[TBL] [Abstract][Full Text] [Related]
18. [Gene transfer of murine Flt3 ligand mediated by adenoviral vector efficiently induces growth inhibition of murine liver cancer].
Yang Q; Yang G; Wei L; Jia F; Wu M; Guo Y
Zhonghua Yi Xue Za Zhi; 2002 Jun; 82(11):775-9. PubMed ID: 12126551
[TBL] [Abstract][Full Text] [Related]
19. Intranasal therapy with an adenoviral vector containing the murine interleukin-12 gene eradicates osteosarcoma lung metastases.
Worth LL; Jia SF; Zhou Z; Chen L; Kleinerman ES
Clin Cancer Res; 2000 Sep; 6(9):3713-8. PubMed ID: 10999765
[TBL] [Abstract][Full Text] [Related]
20. [Differentiated treatment protocols for high- and standard-risk hepatoblastoma--an interim report of the German Liver Tumor Study HB99].
Häberle B; Bode U; von Schweinitz D
Klin Padiatr; 2003; 215(3):159-65. PubMed ID: 12778356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]